There is little time left for Apellis Pharmaceuticals Inc (APLS) to reach its 1-year target estimate. How soon will it surpass it?
Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares traded 2.15% higher at $39.67 on Wall Street last session. In accordance with the data, 14 analysts cover Apellis Pharmaceuticals Inc (NASDAQ:APLS). The consensus rating among analysts is ‘Overweight’. APLS stock price is now 9.11% away from the 50-day moving average and -35.97% away from the 200-day moving average. The […]
Do you still think Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is worth a look?
In yesterday’s Wall Street session, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares traded at $48.53, up 0.48% from the previous session. As of this writing, 15 analysts cover Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $95.00 and a […]
There’s Something Awry at Apellis Pharmaceuticals Inc. (NASDAQ:APLS) Since Share Price Gets Ahead of Fundamentals
The stock of Apellis Pharmaceuticals Inc. (NASDAQ:APLS) last traded at $32.72, down -3.45% from the previous session. Data from the available sources indicates that Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is covered by 15 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of […]
Apellis Pharmaceuticals Inc. (NASDAQ:APLS): A Fundamentally Weighted Stock for Long-Term Investors
The stock of Apellis Pharmaceuticals Inc. (NASDAQ:APLS) last traded at $24.11, up 1.95% from the previous session. Data from the available sources indicates that Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is covered by 15 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of […]
Do you still think Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is worth a look?
In yesterday’s Wall Street session, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares traded at $40.00, down -23.75% from the previous session. As of this writing, 15 analysts cover Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $156.00 and a […]
